❌

Reading view

From Editor to Dense Geometry Estimator

arXiv:2509.04338v2 Announce Type: replace-cross Abstract: Leveraging visual priors from pre-trained text-to-image (T2I) generative models has shown success in dense prediction. However, dense prediction is inherently an image-to-image task, suggesting that image editing models, rather than T2I generative models, may be a more suitable foundation for fine-tuning. Motivated by this, we conduct a systematic analysis of the fine-tuning behaviors of both editors and generators for dense geometry estimation. Our findings show that editing models possess inherent structural priors, which enable them to converge more stably by ``refining" their innate features, and ultimately achieve higher performance than their generative counterparts. Based on these findings, we introduce \textbf{FE2E}, a framework that pioneeringly adapts an advanced editing model based on Diffusion Transformer (DiT) architecture for dense geometry prediction. Specifically, to tailor the editor for this deterministic task, we reformulate the editor's original flow matching loss into the ``consistent velocity" training objective. And we use logarithmic quantization to resolve the precision conflict between the editor's native BFloat16 format and the high precision demand of our tasks. Additionally, we leverage the DiT's global attention for a cost-free joint estimation of depth and normals in a single forward pass, enabling their supervisory signals to mutually enhance each other. Without scaling up the training data, FE2E achieves impressive performance improvements in zero-shot monocular depth and normal estimation across multiple datasets. Notably, it achieves over 35\% performance gains on the ETH3D dataset and outperforms the DepthAnything series, which is trained on 100$\times$ data. The project page can be accessed \href{https://amap-ml.github.io/FE2E/}{here}.
  •  

<i>LRRK2</i>-targeting antisense oligonucleotide in Parkinson’s disease: a phase 1 randomized controlled trial

Nature Medicine, Published online: 24 March 2026; doi:10.1038/s41591-026-04262-4

The first-in-human clinical trial of the LRRK2-targeting antisense oligonucleotide BIIB094 in Parkinson’s disease demonstrates that the treatment is well tolerated and produces dose-dependent reductions in cerebrospinal fluid levels of LRRK2 and phosphorylated Rab10, indicating successful target engagement.
  •  

Spatial Omics in Gastrointestinal Oncology: Recent Advances, Therapeutic Insights, and Clinical Translation

J Cancer. 2026 Jan 30;17(3):515-523. doi: 10.7150/jca.127381. eCollection 2026.

ABSTRACT

Gastrointestinal (GI) cancers remain a leading cause of cancer-related morbidity and mortality worldwide, largely due to their molecular heterogeneity, complex tumor microenvironment (TME), and variable treatment responses. In recent years, the emergence of spatially resolved omics technologies-encompassing spatial transcriptomics, proteomics, metabolomics, and epigenomics-has revolutionized the ability to interrogate tumor architecture with unprecedented resolution. These methods enable precise mapping of cellular and molecular interactions within intact tissue contexts, thereby uncovering spatially defined niches that influence tumor progression, immune evasion, and therapeutic resistance. In GI malignancies such as colorectal, gastric, and esophageal cancers, spatial omics have provided critical insights into cancer-stromal-immune crosstalk, identified predictive biomarkers for immunotherapy and targeted agents, and guided the development of novel therapeutic strategies. This review synthesizes the latest advances in spatial omics applied to GI oncology over the past five years, with an emphasis on their integration into early diagnosis, treatment stratification, and real-time monitoring of therapeutic efficacy. We also discuss current challenges, including standardization, data integration, and clinical validation, as well as future directions for incorporating spatial profiling into routine oncology practice. By bridging the gap between bench discoveries and bedside applications, spatial omics hold transformative potential for achieving truly personalized treatment in gastrointestinal cancers.

PMID:41869445 | PMC:PMC13003551 | DOI:10.7150/jca.127381

  •  
❌